GV20 Therapeutics
PrivateLast Round
Early Funding
Feb 1, 2025
Total Funding Raised
$30M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
GV20 Therapeutics operates in Healthcare & Life Sciences and is based in Newton, Massachusetts. Its latest recorded funding round was an Early Funding round in February 2025.
GV20 Therapeutics is a biotechnology company that develops antibody therapeutics for cancer treatment by integrating artificial intelligence, genomics, and cancer biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GV20 Therapeutics Comparables
Compare GV20 Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adcentrx Therapeutics | 80% | |
| Hummingbird Bioscience | 78% | |
| Generate Biomedicines | 71% |
For institutional investors. Book with your work email.
GV20 Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Feb 1, 2025 | ||||
| Series B | Oct 14, 2021 | ||||
| Series A | Oct 2, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GV20 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IDG Capital | Series B, Series A |
| Linear Capital | Series B, Series A |
| Coatue Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 195% MoM, reaching 3.7K.
- Mar 17, 2026
Selected to deliver late-breaking oral presentation on product GV20-0251.
For institutional investors. Book with your work email.
GV20 Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GV20 Therapeutics's valuation, stock price, and market status.
Is GV20 Therapeutics a public or private company?
GV20 Therapeutics is a private company.
What is the current stock price of GV20 Therapeutics?
GV20 Therapeutics is a private company, so its shares have no public market price. Caplight tracks GV20 Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GV20 Therapeutics worth (valuation)?
Valuation information for GV20 Therapeutics is not publicly available.
Can I buy GV20 Therapeutics stock?
GV20 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GV20 Therapeutics's last funding round?
GV20 Therapeutics's most recent funding round was Early Funding on February 1, 2025.
Who are the main investors in GV20 Therapeutics?
Key investors in GV20 Therapeutics include Coatue Management.
Will GV20 Therapeutics IPO soon?
No public IPO plans have been announced for GV20 Therapeutics.
How can I track GV20 Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GV20 Therapeutics's shares on secondary markets.